Sabina Chiaretti | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel	BLOOD	2024
Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL	JOURNAL OF CLINICAL ONCOLOGY	2024
Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel	BLOOD	2024
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study	HAEMATOLOGICA	2024
Ponatinib alone or with chemo-immunotherapy in heavily pre-treated Philadelphia-like acute lymphoblastic leukemia: a CAMPUS ALL real-life study	HAEMATOLOGICA	2024
CD146 MOLECULE EXPRESSION IN B CELLS ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALLs): A FLOW- CYTOMETRIC MARKER FOR AN ACCURATE DIAGNOSTIC WORK-UP	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2024
Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia	BLOOD	2024
A five-gene signature may associate with central nervous system dissemination in adult acute lymphoblastic leukemia	HEMATOLOGICAL ONCOLOGY	2023
Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia	CANCERS	2023
DROPLET DIGITAL PCR DETECTION OF THE T315I BCR::ABL1 KD MUTATION IN ADULT PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA	European Hematology Association (EHA) 2023 Open Library	2023
Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase	LEUKEMIA & LYMPHOMA	2023
Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia	CANCERS	2023
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study	HAEMATOLOGICA	2023
Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia	CANCERS	2023
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial	BLOOD ADVANCES	2023
Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study	BLOOD CANCER JOURNAL	2023
Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia	CANCERS	2023
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study	CANCERS	2023
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front‐line with paediatric‐inspired regimens: A retrospective multicentre Campus ALL study	BRITISH JOURNAL OF HAEMATOLOGY	2023
Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study	BRITISH JOURNAL OF HAEMATOLOGY	2023

Progetti di Ricerca

Dissecting and redefining the interplay between minimal residual disease and genetic features of Ph-like ALL:
The BCR/ABL1-like acute lymphoblastic leukemia (ALL) predictor: refinement of clinical and biological features of BCR/ABL1-like ALL patients, and validation and reproducibility of the diagnostic method